Predict your next investment

Family Office

See what CB Insights has to offer

Investments

22

Portfolio Exits

4

About Euclidean Capital

Euclidean Capital is the family office for hedge fund billionaire James Simons.

Euclidean Capital Headquarter Location

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Euclidean Capital

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Euclidean Capital in 1 Expert Collection, including Pharma Startups.

P

Pharma Startups

5,090 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

Latest Euclidean Capital News

Ribon Therapeutics Raises $65M in Funding

Jul 14, 2021

Ribon Therapeutics , a Cambridge, Mass.-based clinical stage biotechnology company developing therapeutics targeting stress support pathways in cancer and inflammation, closed a $65m financing. The round was led by Deerfield Management and U.S. Venture Partners, with support from new investors Avego BioScience Capital, GV (formerly Google Ventures), Monashee Investment Management and Peregrine Ventures, along with existing investors AbbVie Ventures, Bristol Myers Squibb, Euclidean Capital, Johnson & Johnson Innovation – JJDC, Inc., Novartis Venture Fund, Osage University Partners, Takeda Ventures and The Column Group. The company will use the proceeds to support the clinical development of its novel precision medicine candidates. Led by Victoria Richon, Ph.D., President and Chief Executive Officer, Ribon Therapeutics is a clinical stage biotechnology company developing therapeutics targeting novel enzyme families activated under cellular stress conditions that contribute to disease. The company is exploring novel areas of biology to develop effective treatments for patients with limited therapeutic options. Leveraging its proprietary BEACON+ (Blocking the Enzyme Activity Component of NAD+) platform, the company is building a pipeline of selective, small molecule inhibitors to numerous NAD+-utilizing enzymes, beginning with monoPARPs, which have applications across multiple therapeutic areas. The lead program is RBN-2397, a PARP7 inhibitor in clinical development for the treatment of cancer. FinSMEs 14/07/2021

Euclidean Capital Investments

22 Investments

Euclidean Capital has made 22 investments. Their latest investment was in Ribon Therapeutics as part of their Series C on July 7, 2021.

CBI Logo

Euclidean Capital Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

7/14/2021

Series C

Ribon Therapeutics

$65M

No

AbbVie Ventures, Avego Healthcare Capital, Bristol-Myers Squibb, Deerfield Management, Google Ventures, Johnson & Johnson Innovation, Monashee Investment Management, Novartis, Osage University Partners, Peregrine Ventures, Takeda Ventures, The Column Group, and U.S. Venture Partners

3

6/17/2021

Series C

Circle Pharma

$66M

Yes

Eli Lilly and Company, Hartford HealthCare Endowment, Nextech Invest, Pandect Bioventures, Pavilion Capital, and The Column Group

4

6/3/2021

Series A

Stablix Therapeutics

$63M

Yes

Alexandria Real Estate Equities, Cormorant Asset Management, New Enterprise Associates, and Versant Ventures

3

5/19/2021

Series C

Subscribe to see more

$99M

Subscribe to see more

10

3/23/2021

Series B

Subscribe to see more

$99M

Subscribe to see more

10

Date

7/14/2021

6/17/2021

6/3/2021

5/19/2021

3/23/2021

Round

Series C

Series C

Series A

Series C

Series B

Company

Ribon Therapeutics

Circle Pharma

Stablix Therapeutics

Subscribe to see more

Subscribe to see more

Amount

$65M

$66M

$63M

$99M

$99M

New?

No

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

AbbVie Ventures, Avego Healthcare Capital, Bristol-Myers Squibb, Deerfield Management, Google Ventures, Johnson & Johnson Innovation, Monashee Investment Management, Novartis, Osage University Partners, Peregrine Ventures, Takeda Ventures, The Column Group, and U.S. Venture Partners

Eli Lilly and Company, Hartford HealthCare Endowment, Nextech Invest, Pandect Bioventures, Pavilion Capital, and The Column Group

Alexandria Real Estate Equities, Cormorant Asset Management, New Enterprise Associates, and Versant Ventures

Sources

3

4

3

10

10

Euclidean Capital Portfolio Exits

4 Portfolio Exits

Euclidean Capital has 4 portfolio exits. Their latest portfolio exit was 23andMe on June 17, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

6/17/2021

Reverse Merger

$991

13

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

$991

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

$991

Subscribe to see more

10

Date

6/17/2021

00/00/0000

00/00/0000

00/00/0000

Exit

Reverse Merger

Subscribe to see more

Subscribe to see more

Subscribe to see more

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$991

$991

$991

Acquirer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

13

10

10

10

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.